Iftekhar Kalsekar, PhD

          Richard Baldwin, MS

Stanley Garbus, MD, MPH

Renée J. Goldberg Arnold, PharmD, completed her undergraduate training at the University of Maryland and received her Doctor of Pharmacy from the University of Southern California in LA. Dr. Arnold is currently President and CEO, Arnold Consultancy & Technology LLC, NYC, where she develops and oversees outcomes research and affiliated software for industry and federal government. Her special interest in evidence-based health derives from her research that deals with use of technology to collect and/or model real-world data for use in rational healthcare decision-making by healthcare practitioners and policy makers. Dr. Arnold's academic titles include Full Adjunct Professor, Div. of Social Sciences, at LIU, including as a preceptor for students completing rotations in health outcomes and pharmacoeconomics. She is also Adjunct Associate Professor, Master of Public Health program, Department of Community and Preventive Medicine at the Mount Sinai School of Medicine, where she has developed the pharmacoeconomics coursework and is a preceptor for MD/MPH students completing their MPH practicums.

Sean Ekins, PhD, graduated from the University of Aberdeen; receiving his M.Sc., Ph.D. and D.Sc. His areas of interest are in vitro and computational ADME/Tox, biomarkers, systems biology and computational drug discovery. He was a postdoctoral fellow at Lilly Research Laboratories in the drug disposition group. He has worked as a senior scientist at Pfizer and Lilly Research Laboratories in drug-drug interaction screening and computational ADME/Tox groups, respectively and as Associate Director of Computational Drug Discovery at Concurrent Pharmaceuticals, Inc. and Vice President of Computational Biology at GeneGo. He is Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland and Senior Vice President of Computational Biology at Arnold Consultancy and Technology LLC. and Principal Consultant for Collaborations in Chemistry. He has authored or co-authored ~90 peer reviewed papers and book chapters as well as edited two books. He is Associate Editor of the Journal of Pharmacological and Toxicological Methods, on the Editorial Board of Drug Metabolism and Disposition, Drug Discovery Today, Current Drug Metabolism, Drug Metabolism Letters as well as the Editorial Advisory Board for Pharmaceutical Research. 

Sarah Evans, utilizing her international career with clinical trials, technology and medical devices, joined Arnold Consultancy and Technology LLC as Vice President, Evidence-Based Health. She was formerly the Clinical Trials Data Manager for Jarvik Heart. With the NYC Leukaemia and Lymphoma Society she spearheads their Clinical Trials Advocacy, and is the inaugural co-chair of the Medical Device and Diagnostic Affinity for the HBA. While in Australia, she worked with AusBiotech, the peak Biotechnology industry body, to implement the Medical Device Network Industry Action Agenda; liaising with regulators at the TGA (their FDA), and Government. Previously she was the UK Director for Advanced Bionics, the Cochlear Implant/Pain division of Boston Scientific, and involved the 'end-users' by developing an award-winning Internet presence www.ci-4teenz.com. She holds post-graduate diplomas in Cardiac Technology & Management, studied Business Administration at the University of Denver and her undergraduate training at the University Hospital of Wales in Medical Physics.

Richard Baldwin, CIO, has worked with Arnold Consultancy and Technology since its inception.  He has over 20 years' experience developing and then supervising multiple types of software development for international companies and has worked extensively with Dr Arnold and ACT to develop web applications for our customers.  With an MS in Computer Science from Columbia University, he also holds a BA in Special Honors Curriculum; BA in Economics, Summa Cum Laude; and a BA in Computer Science, Summa Cum Laude, Hunter College.